论文信息 - Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. - 字舞流文

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

H. Wakelee | A. Tolcher | B. Sikic | A. Patnaik | M. Mita | G. Fisher | N. Fox | R. Miceli | S. Ullrich | George A. Fisher | G. A. Fisher